- Details
- Stacy Loeb discusses with Alicia Morgans her successful implementation of a Twitter-based prostate cancer journal club for patients that was implemented in 2017, under #prostatejc. They also discuss the necessity to vet the quality of information available to consumers. Stacy refers to a content analysis of YouTube videos related to prostate cancer, published in 2017 in the American Journal of Men...
|
- Details
- Wassim Abida joins Charles Ryan in a discussion on a JAMA Oncology published paper on the Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. Wassim details the prevalence of MSI-H/dMMR prostate cancer and the clinical benefit of anti–PD-1/programmed cell death 1 ligand 1 (PD-L1) therapy in this molecularly defined population. The...
|
- Details
- Charles Ryan interviews Alicia Morgans on her thoughts about treatment decision making in the metastatic hormone-sensitive prostate cancer (mHSPC) population and changes that are rapidly developing in this area. They review how studies such as CHAARTED, LATITUDE, and STAMPEDE have shaped the current options. The discuss the next sets of data that are expected to further expand treatment options in...
|
- Details
- Howard Soule, Executive Vice President & Chief Science Officer of the Prostate Cancer Foundation highlights PCFs 25th-year milestone in shaping the direction of prostate cancer research in this conversation with Alicia Morgans. Howard shares how the foundation was started, how it is impacting prostate cancer research and the future directions of the foundations impactful work. Howard shares his pe...
|
- Details
- Richard Lee, a 2017 PCF Challenge Award recipient, discusses his research on the metabolics of prostate cancer. The upcoming Phase 1 research in men with CRPC is centered around inhibiting the glutaminase pathway in combination with a PARP inhibitor. The rationale for targeting the glutaminase pathway stems from the fact that cancer cells deplete glucose as a carbon source, a necessary element for...
|
- Details
- In this conversation, Mary-Ellen Taplin reviews her work from the past nine years in the area of neoadjuvanct therapies prior to prostatectomy. Mary-Ellen discusses how research on combining systematic therapy with prostatectomy when next generation androgen-AR axis inhibitors were developed have now lead to the launch of a large, international phase 3 trial. Biographies: Mary-Ellen Taplin, MD Cha...
|
- Details
- Maha Hussain joins Alicia Morgans and reflects on the journey she has traveled from 1983 when prostate cancer was viewed as a disease exclusive to older men, where there were no real biomarkers and a lack of understanding for the spectrum of the disease. Maha delivers one of the pivotal talks at the PCF 25th Annual retreat and here we gain her perspective on the evolving landscape of life-prolongi...
|
- Details
- Hala Borno and Charles Ryan discuss the ongoing and increasing problems in the enrollment of clinical trials in oncology. Hala describes her goals in this area and her passion for uncovering differences that lead to inequities. Hala is currently developing a patient facing tool called Trial Library, that is a clinical trial online matching website developed based on patient-prompted conversations...
|
- Details
- Lorelei Mucci and Alicia Morgans discuss the findings of a large epidemiologic study examining physical activity and its influence on a wide range of biological processes including anti-inflammatory and insulin pathways, may be linked to a lower risk of prostate cancer. In addition to being one of the largest of its kind, the study stands out in that researchers were able to examine medical record...
|
- Details
- Suresh C. Srivastava presents the unique opportunities and future for nuclear medicine, including theragnostic radiopharmaceuticals for molecular imaging plus therapy and getting closer to personalized medicine, selection criteria, production, and the nuclear, physical, and chemical properties of certain dual-purpose radionuclides, including those that are currently being used, or studied and eval...
|
